Tag:

Perrigo

Latest Headlines

Latest Headlines

Undeterred by Perrigo rejection, Mylan tells Teva to step off

On Friday, Mylan all but rejected Teva's takeover bid with its own sweetened bid for Ireland's Perrigo. But now, it's made the snub official, delivering a resounding "no" to its generics rival.

Mylan recalls injected cancer meds made for Pfizer

Mylan may be fending off an unsolicited $40 billion buyout offer from competitor Teva even as it is being rebuffed for making its own $31 billion bid for Perrigo, but it still has to take care of business as usual. Right now that includes having to recall 8 lots of injectable cancer drugs, most of it manufactured for Pfizer, after particulate was discovered in vials.

Hours after receiving new bid, Perrigo tells Mylan to take a hike

Just a couple hours after Mylan sweetened its original bid for Ireland's Perrigo to $31 billion-plus, Perrigo nixed the new offer. Why? The way the target sees it, it isn't quite so sweet.

In an affront to Teva, Mylan hikes Perrigo offer past $31B

Mylan sent a message to Teva that it wasn't interested in becoming bait even before the Israeli drugmaker made its $40 billion bid earlier this week. Now, it's repeating that message loud and clear--and it's doing so with a sweetened offer for Irish target Perrigo.

Teva wants Mylan wants Perrigo, and the pundits go mad with opinions

Rumors of a Teva-Mylan merger have swirled for weeks, and now that Teva's bid has actually arrived, the talk is heating up even more. Everyone has an opinion--Mylan and Teva included--and those opinions are all over the map. Strategic or not? Legally possible or not? At what price might Mylan be willing to talk? And could Mylan persuade the reluctant Perrigo to take its (defensive) $29 billion offer? 

Perrigo spurned Mylan's $29B offer, but would a bigger one do?

Bad news for Mylan if it wants to avoid a $40 billion takeover by generics rival Teva: Its own acquisition prospect, Ireland's Perrigo, isn't interested in getting together.

Mylan seeks entry into animal health via $29B bid for Perrigo

When Mylan offered to buy Perrigo for $205 per share last Wednesday, the brewing $29 billion bid was hailed as the giant generics deal Wall Street has been anticipating. But this deal has an animal health angle too: If Mylan pulls it off, the acquisition will mark its entry into the veterinary market.

Will Mylan's $29B bid spur other Perrigo suitors to enter the fray?

More than a couple of analysts agree that there may be a company out there that's after Mylan--and that that could have prompted the company's $28.9 billion bid for Ireland's Perrigo. But now that Mylan's made its offer, could that spur other Perrigo offers, too?

Was Mylan's $29B Perrigo bid a takeover defense? Analysts say yes

Since Mylan went public on Wednesday with a $205-per-share buyout offer for Ireland's Perrigo, analysts have been weighing the pros and cons of a tie-up between the two generics makers. But there's one thing at least a few of them agree on: The $29 billion bid has to be a response to other M&A action going on behind the scenes.

Mylan makes a pass at Perrigo with $205-per-share buyout offer

Generics specialist Mylan has zeroed in on the big buyout everyone's been waiting for. The Pittsburgh-based drugmaker offered $205 per share for Perrigo, the over-the-counter drugmaker that just closed its own $4.5 billion deal for Belgium's Omega Pharma.